Skip to content

Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing

Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02067962
Acronym
GenesinJIA
Enrollment
30
Registered
2014-02-20
Start date
2014-03-05
Completion date
2015-06-24
Last updated
2020-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Juvenile Rheumatoid

Keywords

Juvenile idiopathic arhtritis, JIA, Gene identification, Whole exome sequencing, Next generation sequencing, Identification of molecular basis, Acceptation of both parents to participate to the study

Brief summary

Juvenile idiopathic arthritis (JIA) is considered to be a multifactorial disease caused by a combination of environmental factors and predisposing genetic factors. Twins studies found a strong heritability (strong genetic factors) but genetic studies such association studies of large cohorts of patient (GWAS or Genome Wide Association Study) have elucidated less than 20 % of the genetic basis of JIA. The vision of the genetics of multifactorial diseases has recently changed revealing a large clinical and genetic heterogeneity of these diseases. Indeed, the advent of next-generation sequencing identified non-multifactorial genetic hereditary disease related to mutations in genes having strong effect on the onset of the disease without real impact of environmental factors among the so called multifactorial diseases (Parkinson's, diabetes, osteoarthritis, Alzheimer's, hypertension ...)The investigators propose to study 30 families with several forms of JIA by next-generation sequencing. Identifying the genetic basis of JIA in these families will help to better understand the physiopathology of this disease and may help to the identification of novel therapeutic targets for other patients with JIA.

Interventions

BIOLOGICALBlood sample

Blood sample

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Months to 40 Years
Healthy volunteers
No

Inclusion criteria

* AJI oligoarticular form \<4 joints * AJI Polyarticular form\> 4 joints * AJI Forms systemic arthritis * duration For more than six weeks * Onset of symptoms before the age of 16 years * Or rheumatoid factor or ANA + or CCP +Acceptation of both parenth to participate to the research and to perfom blood samples for genetic studies

Exclusion criteria

* The (the) patient (e) is under tutorship or curatorship * The (the) patient (e) is under judicial protection * The (the) patient (e), or his parents, refuses to sign the consent * It is impossible to give (the) patient (e) information lit * JIA spondyloarthropathies such * JIA type psoriatic arthritis or enthesopathy * JIA not classifiable

Design outcomes

Primary

MeasureTime frameDescription
Identification of new genes by Next Generation Squencing (NGS)1 dayIdentification of new genes by Next Generation Squencing (NGS) in order to propose a new classification for prognosis and therapeutic orientation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026